Willingness to accept vaccination against SARS-cov-2: A survey of junior doctors

Introduction: The Coronavirus disease 2019 (COVID-19) has become a cause of significant morbidity and mortality in the world. There are currently 4 COVID-19 vaccines have been developed for mass vaccination to combat the disease. Some people, however, have expressed safety and efficacy concerns with regards to the vaccines. In Ghana, junior doctors, being frontline doctors, are likely to first encounter patients presenting with COVID-19. They may also have the highest direct exposure to the virus even though their outcomes after infection may be good. The study sought to determine the potential acceptance rate of COVID-19 vaccine among junior doctors, the factors that will influence their acceptance and whether they will recommend the vaccine to their patients. Methods: The study was an ethically approved anonymous cross-sectional survey to determine the willingness to accept the SARS-CoV-2 vaccine among junior doctors in Ghana. The survey was designed using Google forms posted to the various junior doctor’s social media group pages such as WhatsApp and Facebook with the study participants responding to 15 items. Results: Out of a total of 305 participants, females were 155 (50.8%). Of the respondents, 171/305 (56.1%) had cared for Covid-19 patients before, 51/305 (16.7%) had had Covid-19 infection previously and 204/305 (66.9%) will be willing to take the vaccine when available. Females were more likely to take the vaccine and those who were willing to accept the vaccine were more likely to recommend same to their family and others. Conclusion: This study has showed a more than average willingness to accept the COVID-19 vaccine. Female gender, living with the extended family and history of SARS-Cov-2 infection were positively associated with willingness to accept the COVID-19 vaccine. Doctors who were willing to accept the vaccine were also more likely to recommend their patients and family members to also accept the COVID-19 vaccine.